Abstract
Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 182-188 |
| Number of pages | 7 |
| Journal | Cancer Investigation |
| Volume | 25 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 2007 |
Fingerprint
Keywords
- Carboplatin
- Chemotherapy
- Docetaxel
- Head and neck cancer
- Taxane
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. / Samlowski, Wolfram E.; Moon, James; Kuebler, J. Philip; Nichols, Craig R.; Gandara, David R; Ozer, Howard; Williamson, Stephen K.; Atkins, James N.; Schuller, David E.; Ensley, John F.
In: Cancer Investigation, Vol. 25, No. 3, 04.2007, p. 182-188.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
T2 - A Southwest Oncology Group phase II study
AU - Samlowski, Wolfram E.
AU - Moon, James
AU - Kuebler, J. Philip
AU - Nichols, Craig R.
AU - Gandara, David R
AU - Ozer, Howard
AU - Williamson, Stephen K.
AU - Atkins, James N.
AU - Schuller, David E.
AU - Ensley, John F.
PY - 2007/4
Y1 - 2007/4
N2 - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.
AB - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.
KW - Carboplatin
KW - Chemotherapy
KW - Docetaxel
KW - Head and neck cancer
KW - Taxane
UR - http://www.scopus.com/inward/record.url?scp=34347270591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347270591&partnerID=8YFLogxK
U2 - 10.1080/07357900701209061
DO - 10.1080/07357900701209061
M3 - Article
C2 - 17530488
AN - SCOPUS:34347270591
VL - 25
SP - 182
EP - 188
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 3
ER -